Ulcer and gastritis

Endoscopy

Volumn 39, Issue 2, 2007, Pages 101-105

  Kashiwagi, H ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CHOLECYSTOKININ; CYTOKINE; DICLOFENAC; ESOMEPRAZOLE; GARLIC EXTRACT; GASTRIN; GROWTH FACTOR; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PEPSINOGEN; PLACEBO; PROSTAGLANDIN; PROTON PUMP INHIBITOR; RANTES; REACTIVE OXYGEN METABOLITE; VITAMIN;

ARTICLE; CANCER RISK; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG MEGADOSE; ENDOSCOPIC THERAPY; GASTRITIS; GASTROSCOPY; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LAPAROSCOPIC SURGERY; MEDLINE; META ANALYSIS; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRECANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STOMACH BIOPSY; STOMACH CANCER; SYSTEMATIC REVIEW; TREATMENT INDICATION; ULCER PERFORATION;

BIOLOGICAL MARKERS; GASTRITIS; GASTROSCOPY; HELICOBACTER INFECTIONS; PEPTIC ULCER HEMORRHAGE; PEPTIC ULCER PERFORATION; PRECANCEROUS CONDITIONS; RISK FACTORS; STOMACH ULCER;

EID: 33947101570     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-945108     Document Type: Article

References (23)

1. Dixon ME, Genta RM, Yardley JH et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161-1181
2. Naito Y, Ito M, Watanabe T et al. Biomarkers in patients with gastric inflammation: a systematic review. Digestion 2005; 72: 164-180
3. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology 2006; 130: 188-206
4. Ouburg S, Bart A, Crusius J et al. A candidate gene approach of immune mediators effecting the susceptibility to and severity of upper gastrointestinal tract diseases in relation to Helicobacter pylori and Epstein-Barr virus infections. Eur J Gastroenterol Hepatol 2005; 17: 1213-1224
5. Tsai CJ, Herrera-Goepfert R, Tibshirani RJ et al. Changes of gene expression in gastric preneoplasia following Helicobacter pylori eradication therapy. Cancer Epidemiol Biomarkers Prev 2006; 15: 272-280
6. Lu B, Chen MT, Fan YH et al. Effects of Helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a 3-year follow-up study. World J Gastroenterol 2005; 11: 6518-6520
7. Mera R, Fontham ET, Bravo LE et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54: 1536-1540
8. You WC, Brown LM, Zhang L et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-983
9. You WC, Zhang L, Grail MH et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 2000; 92: 1607-1612
10. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 331: 1310-1316
11. Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-710
12. Huang J-Q, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 13-22
13. Papatheodoridis GV, Sougioultzis S, Archimandiltis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterot Hepatol 2006; 4: 130-142
14. Lin HJ, Lo WC, Cheng YC et al. Role of intravenous omeprazole in patients with high-risk peptic ulcer bleeding after successful endoscopic epinephrine injection: a prospective randomized comparative trial. Am J Gastroenterol 2006; 101: 500-505
15. Andrews CN, Levy A, Fishman M et al. Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high-risk stigmata: a multicentre comparative study. Can J Gastroenterol 2005; 19: 667-671
16. Cook DJ, Guyatt GH, Salena BJ et al. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterolgy 1992; 102: 139-148
17. Consensus conference: therapeutic endoscopy and rebleeding ulcers (review). JAMA 1989; 262: 1369-1372
18. Kahi CJ, Jensen DM, Sung JJ et al. Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology 2005; 129: 855-862
19. Lau WY, Leong KI, Kwong KH et al. A randomized study comparing laparoscopic versus open repair of perforated peptic ulcer using suture or sutureless technique. Ann Surg 1996; 224: 131-138
20. Siu WT, Leong KI, Law BK et al. Laparoscopic repair for perforated peptic ulcer: a randomized controlled trial. Ann Surg 2002; 235: 313-319
21. Lunevicius R, Morkevicius M. Systematic review comparing laparoscopic and open repair for perforated peptic ulcer. Br J Surg 2005; 92: 1195-1207
22. Lunevicius R, Morkevicius M. Management strategies, early results, benefits, and risk factors of laparoscopic repair of perforated peptic ulcer. World J Surg 2005; 29: 1299-1310
23. Boey J, Choi SK, Poon A et al. Risk stratification in perforated duodenal ulcer: a prospective validation of predictive factors. Ann Surg 1987; 205: 22-26